B. Keating Laurie's Insider Trades & SAST Disclosures
B. Keating Laurie's most recent trade in Immuneering Corp - Ordinary Shares Class A was a trade of 23,485 Stock Option done . Disclosure was reported to the exchange on Jan. 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern B. Keating Laurie.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immuneering Corp - Ordinar... | B. Keating Laurie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 23,485 | 23,485 | - | - | Stock Option | |
| PepGen Inc | Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Immuneering Corp - Ordinar... | Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 33,350 | 33,350 | - | - | Stock Option | |
| Immuneering Corp - Ordinar... | Keating B. Laurie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 6,879 | 6,879 | - | - | Stock Option | |
| PepGen Inc | Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Immuneering Corp - Ordinar... | Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option | |
| Immuneering Corp - Ordinar... | Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 14,200 | 14,200 | - | - | Stock Option | |
| Immuneering Corp - Ordinar... | Laurie B. Keating | Director | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 16 May 2022 | 7,000 | 14,000 | - | 5 | 35,000 | Class A Common Stock |
| PepGen Inc | Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 5,833 | 5,833 | - | - | Stock Option (Right to Buy) | |
| PepGen Inc | Laurie B. Keating | Director | Purchase of securities on an exchange or from another person at price $ 12.00 per share. | 06 May 2022 | 4,166 | 4,166 | - | 12 | 49,992 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 188.95 per share. | 05 Aug 2021 | 10,000 | 5,132 (0%) | 0% | 189.0 | 1,889,500 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 7,876 | 1,124 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 05 Aug 2021 | 7,876 | 13,008 (0%) | 0% | 88.9 | 700,570 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 2,124 | 11,876 | - | - | Performance Stock Option 2015 (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 05 Aug 2021 | 2,124 | 15,132 (0%) | 0% | 89.0 | 188,930 | Common Stock |
| Immuneering Corp - Ordinar... | Laurie B. Keating | Director | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 03 Aug 2021 | 7,000 | 7,000 | - | 15 | 105,000 | Class A Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 178.95 per share. | 12 Jul 2021 | 5,000 | 5,132 (0%) | 0% | 179.0 | 894,750 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 5,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 12 Jul 2021 | 5,000 | 11,944 (0%) | 0% | 89.0 | 444,750 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 1,812 | 17,188 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.00 per share. | 12 Jul 2021 | 1,812 | 6,944 (0%) | 0% | 85 | 154,020 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 179.00 per share. | 12 Jul 2021 | 1,812 | 10,132 (0%) | 0% | 179 | 324,348 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 154.00 per share. | 09 Jun 2021 | 1,734 | 5,132 (0%) | 0% | 154 | 267,036 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 4,518 | 8,955 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.75 per share. | 19 Apr 2021 | 2,014 | 6,941 (0%) | 0% | 131.8 | 265,345 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.41 per share. | 19 Apr 2021 | 75 | 6,866 (0%) | 0% | 134.4 | 10,081 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 17,846 | 17,846 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 4,584 | 10,000 | - | - | Performance Stock Option 2017 (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 4,166 | 6,400 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.00 per share. | 11 Feb 2021 | 1,857 | 4,543 (0%) | 0% | 156 | 289,692 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.54 per share. | 11 Feb 2021 | 106 | 4,437 (0%) | 0% | 153.5 | 16,275 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.00 per share. | 13 Jan 2021 | 6,000 | 11,261 (0%) | 0% | 85 | 510,000 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 6,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 169.00 per share. | 13 Jan 2021 | 5,000 | 6,261 (0%) | 0% | 169 | 845,000 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 3,027 | 2,164 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.40 per share. | 13 Jan 2021 | 3,027 | 5,261 (0%) | 0% | 77.4 | 234,290 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 170.00 per share. | 13 Jan 2021 | 3,000 | 3,261 (0%) | 0% | 170 | 510,000 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 174.00 per share. | 13 Jan 2021 | 1,027 | 2,234 (0%) | 0% | 174 | 178,698 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2021 | 13,000 | 5,191 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.40 per share. | 11 Jan 2021 | 13,000 | 17,175 (0%) | 0% | 77.4 | 1,006,200 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 159.00 per share. | 11 Jan 2021 | 11,941 | 5,234 (0%) | 0% | 159 | 1,898,619 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 165.00 per share. | 11 Jan 2021 | 3,000 | 2,234 (0%) | 0% | 165 | 495,000 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2021 | 1,941 | 2,370 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.22 per share. | 11 Jan 2021 | 1,941 | 4,175 (0%) | 0% | 42.2 | 81,949 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 154.00 per share. | 11 Jan 2021 | 758 | 2,234 (0%) | 0% | 154 | 116,732 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2020 | 23,809 | 18,191 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.40 per share. | 13 Jul 2020 | 23,809 | 40,242 (0%) | 0% | 77.4 | 1,842,817 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 161.32 per share. | 13 Jul 2020 | 15,618 | 12,522 (0%) | 0% | 161.3 | 2,519,496 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 160.52 per share. | 13 Jul 2020 | 14,236 | 28,140 (0%) | 0% | 160.5 | 2,285,163 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 162.24 per share. | 13 Jul 2020 | 9,530 | 2,992 (0%) | 0% | 162.2 | 1,546,147 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2020 | 6,250 | 7,500 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 119.13 per share. | 13 Jul 2020 | 6,250 | 50,242 (0%) | 0% | 119.1 | 744,563 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 157.16 per share. | 13 Jul 2020 | 4,482 | 45,760 (0%) | 0% | 157.2 | 704,391 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2020 | 3,750 | 5,416 | - | - | Performance Stock Option 2017 (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 119.13 per share. | 13 Jul 2020 | 3,750 | 43,992 (0%) | 0% | 119.1 | 446,738 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 158.27 per share. | 13 Jul 2020 | 2,323 | 43,437 (0%) | 0% | 158.3 | 367,661 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.22 per share. | 13 Jul 2020 | 1,941 | 16,433 (0%) | 0% | 42.2 | 81,949 | Common Stock |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2020 | 1,941 | 4,311 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Laurie B. Keating | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 159.22 per share. | 13 Jul 2020 | 1,061 | 42,376 (0%) | 0% | 159.2 | 168,932 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges